Pyrazolidinedione derivatives
    1.
    发明申请
    Pyrazolidinedione derivatives 审中-公开
    吡唑烷二酮衍生物

    公开(公告)号:US20070037846A1

    公开(公告)日:2007-02-15

    申请号:US10562623

    申请日:2004-06-16

    摘要: The present invention relates to compounds of alkylidene pyrazolidinedione derivatives, which are effective platelet ADP receptor antagonists that prevent platelet aggregation and thrombosis. Thus, the present invention also relates to pharmaceutical compositions that contain the compounds as well as methods of preventing or treating peripheral, visceral, hepatic, renal, cardio- and cerebro-vascular diseases and conditions that are associated with platelet aggregation, including thrombosis, in humans and other mammals. The present invention further provides a process for manufacturing the alkylidene pyrazolidinedione derivatives.

    摘要翻译: 本发明涉及亚烷基吡唑烷二酮衍生物的化合物,其是有效的血小板聚集和血栓形成的血小板ADP受体拮抗剂。 因此,本发明还涉及含有化合物的药物组合物以及预防或治疗外周,内脏,肝,肾,心脑血管疾病和与血小板聚集相关的病症的方法,包括血栓形成 人类和其他哺乳动物。 本发明还提供了制备亚烷基吡唑烷二酮衍生物的方法。

    Tetrhydropyridoindole Derivatives
    2.
    发明申请
    Tetrhydropyridoindole Derivatives 审中-公开
    四氢吡啶并吲哚衍生物

    公开(公告)号:US20100234396A1

    公开(公告)日:2010-09-16

    申请号:US12724946

    申请日:2010-03-16

    CPC分类号: C07D471/04

    摘要: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.

    摘要翻译: 本发明涉及四氢吡啶并吲哚衍生物及其在制备药物组合物中作为活性成分的用途。 本发明还涉及包括制备化合物的方法,包含一种或多种这些化合物的药物组合物和包括给药所述化合物的治疗方法的相关方面。

    Tetrahydropyridoindole derivatives
    7.
    发明授权
    Tetrahydropyridoindole derivatives 有权
    四氢吡啶并吲哚衍生物

    公开(公告)号:US07714132B2

    公开(公告)日:2010-05-11

    申请号:US10598777

    申请日:2005-03-07

    IPC分类号: A61K31/4435 C07D457/14

    CPC分类号: C07D471/04

    摘要: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.

    摘要翻译: 本发明涉及四氢吡啶并吲哚衍生物及其在制备药物组合物中作为活性成分的用途。 本发明还涉及包括制备化合物的方法,包含一种或多种这些化合物的药物组合物和包括给药所述化合物的治疗方法的相关方面。

    Tetrahydropyridoindole derivatives
    8.
    发明申请
    Tetrahydropyridoindole derivatives 有权
    四氢吡啶并吲哚衍生物

    公开(公告)号:US20070191416A1

    公开(公告)日:2007-08-16

    申请号:US10598777

    申请日:2005-03-07

    IPC分类号: A61K31/4745 C07D471/02

    CPC分类号: C07D471/04

    摘要: The invention relates to tetrahydropyridoindole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions comprising one or more of those compounds and methods of treatment comprising administration of said compounds.

    摘要翻译: 本发明涉及四氢吡啶并吲哚衍生物及其在制备药物组合物中作为活性成分的用途。 本发明还涉及包括制备化合物的方法,包含一种或多种这些化合物的药物组合物和包括给药所述化合物的治疗方法的相关方面。

    2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists
    9.
    发明授权
    2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists 有权
    2,3,4,9-四氢-1H-咔唑衍生物作为CRTH2受体拮抗剂

    公开(公告)号:US08039474B2

    公开(公告)日:2011-10-18

    申请号:US11722095

    申请日:2005-12-22

    CPC分类号: C07D209/88

    摘要: The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and methods of treatment comprising administration of said compounds to patients.

    摘要翻译: 本发明涉及新四氢-1H-咔唑衍生物及其在制备药物组合物中作为活性成分的用途。 本发明还涉及包括制备化合物的方法,含有一种或多种这些化合物的药物组合物和包括向患者施用所述化合物的治疗方法的相关方面。